Stifel Downgrades Corcept Therapeutics (CORT) to Hold
Tweet Send to a Friend
Stifel downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $20.00.Analyst Adam Walsh says the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE